Karin is the former head of Global Regulatory Affairs at Janssen, the pharmaceutical companies of J&J, now called Johnson & Johnson Innovative Medicines (until April 2023). In this role, Karin led a team of 1200 regulatory affairs professionals across the globe. Under her leadership of Global Regulatory Affairs for 10 years, Janssen has delivered more than 20 medicines with numerous global approvals. Her team has been instrumental in consistently and predictably providing on-time regulatory submissions and approvals, fulfilling Janssen’s promise to patients and society. Driven by her “this is how we can” mindset, GRA at Janssen has become a world-class RA function with an impressive track record. The Therapeutic Areas under Karin’s responsibility were Oncology, Neuroscience, Immunology, Cardiovascular-Metabolism, Retinal Disease, Infectious Diseases including Vaccines. Karin was a key contributor to the development and authorization of Janssen’s COVID vaccine. Prior to her roles at Janssen, she was the head of Global Regulatory Affairs at Tibotec, where she contributed to the global development and worldwide registration of drugs treating HIV, HCV and TB.
